An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 - Owen, Dafydd R.; Allerton, Charlotte M. N.; Anderson, Annaliesa S.; Aschenbrenner, Lisa; Avery, Melissa; Berritt, Simon; Boras, Britton; Cardin, Rhonda D.; Carlo, Anthony; Coffman, Karen J.; Dantonio, Alyssa; Di, Li; et al. (Science (American Association for the Advancement of Science), 2021)
Keywords: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Coronavirus - drug effects; COVID-19 - drug therapy; COVID-19 - virology; Disease Models, Animal; Drug Therapy, Combination; Humans; Lactams - administration & dosage; Lactams - pharmacokinetics; Lactams - pharmacology; Lactams - therapeutic use; Leucine - administration & dosage; Leucine - pharmacokinetics; Leucine - pharmacology; Leucine - therapeutic use; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitriles - administration & dosage; Nitriles - pharmacokinetics; Nitriles - pharmacology; Nitriles - therapeutic use; Proline - administration & dosage; Proline - pharmacokinetics; Proline - pharmacology; Proline - therapeutic use; Randomized Controlled Trials as Topic; Ritonavir - administration & dosage; Ritonavir - therapeutic use; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Viral Protease Inhibitors - administration & dosage; Viral Protease Inhibitors - pharmacokinetics; Viral Protease Inhibitors - pharmacology; Viral Protease Inhibitors - therapeutic use; Virus Replication - drug effects